NCT00002215View on ClinicalTrials.gov

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Emivirine

DRUG

Nelfinavir mesylate

Trial Locations (1)

15213

Anderson Clinical Research, Pittsburgh

Sponsors
All Listed Sponsors
lead

Triangle Pharmaceuticals

INDUSTRY

NCT00002215 - A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive | Biotech Hunter | Biotech Hunter